Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coya Therapeutics Inc (COYA)

Coya Therapeutics Inc (COYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 114,873
  • Shares Outstanding, K 20,924
  • Annual Sales, $ 3,550 K
  • Annual Income, $ -14,880 K
  • EBIT $ -21 M
  • EBITDA $ -21 M
  • 60-Month Beta 0.20
  • Price/Sales 32.32
  • Price/Cash Flow N/A
  • Price/Book 3.37

Options Overview Details

View History
  • Implied Volatility 635.73% (+65.17%)
  • Historical Volatility 47.90%
  • IV Percentile 97%
  • IV Rank 97.34%
  • IV High 650.64% on 12/18/25
  • IV Low 89.67% on 10/22/25
  • Expected Move (DTE 25) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 30
  • Volume Avg (30-Day) 51
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 1,014
  • Open Int (30-Day) 876
  • Expected Range 5.36 to 5.36

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.08
  • Number of Estimates 1
  • High Estimate -0.08
  • Low Estimate -0.08
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.25 +2.10%
on 12/18/25
6.62 -19.03%
on 12/01/25
-0.62 (-10.37%)
since 11/21/25
3-Month
5.10 +5.06%
on 09/24/25
7.75 -30.84%
on 10/14/25
-0.11 (-2.01%)
since 09/22/25
52-Week
4.65 +15.27%
on 04/09/25
8.29 -35.34%
on 03/03/25
+0.12 (+2.29%)
since 12/20/24

Most Recent Stories

More News
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being...

COYA : 5.36 (-2.37%)
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...

COYA : 5.36 (-2.37%)
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update

Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with...

COYA : 5.36 (-2.37%)
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo

COYA 303 is an investigational proprietary biologic combination of low-dose (LD)-IL-2 and GLP-1 receptor agonist (RA) for subcutaneous administration with potential for treating inflammation-driven diseases...

COYA : 5.36 (-2.37%)
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...

COYA : 5.36 (-2.37%)
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...

COYA : 5.36 (-2.37%)
Coya Therapeutics Announces Proposed Public Offering of Common Stock

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients...

COYA : 5.36 (-2.37%)
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function

Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs)...

COYA : 5.36 (-2.37%)
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia

Following the positive interim results in 5 patients announced earlier this year, a total of 9 patients have been enrolled as planned

COYA : 5.36 (-2.37%)
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis

The ALSTARS Trial is a well powered randomized, multi-center, double-blind, placebo-controlled, 24-week    study of COYA 302 in people with Amyotrophic Lateral Sclerosis (ALS)

COYA : 5.36 (-2.37%)

Business Summary

Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing...

See More

Key Turning Points

3rd Resistance Point 6.07
2nd Resistance Point 5.92
1st Resistance Point 5.64
Last Price 5.36
1st Support Level 5.21
2nd Support Level 5.06
3rd Support Level 4.78

See More

52-Week High 8.29
Fibonacci 61.8% 6.90
Fibonacci 50% 6.47
Fibonacci 38.2% 6.04
Last Price 5.36
52-Week Low 4.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar